This month, MLA Diagnostics was selected as a finalist in the Academic Startup Competition 2020. 20 ground-breaking innovations in various fields were selected based on their value proposition, the innovative character of the technology involved, the potential of their business and profit model, and the startup team composition. MLA Diagnostics is pleased to be competing to […]
NLC The European Healthtech Venture Builder has closed Momentum – a € 2.2 mln fund for private investments -within a month. This fund will be invested in 11 innovative healthtech ventures from NLC’s portfolio. With this new way of funding, investors can easily spread their money and hence their risk, and at the same time build […]
The LBDF POP grant will support a Health Technology Assessment project in collaboration with Clinical Epidemiology & Medical Technology Assessment (KEMTA) and HI-NL. The project consisted of 3 phases: patient journey inventory, health economic modelling and an expert round table session including experts from all domains (clinical, insurance, reimbursement, regulatory, health economic and clinical methodology).
MLA Diagnostics has recently received EIT funding from the Headstart program. With this funding the company will boost development the company’s Quality and Regulatory strategy.
LAB1891 and UtrechtInc will partner up to support 3 early stage startups selected by MSD to help innovation in their focus area. The programme provided coaching, workshops and access to a global network of expertise. MLA Diagnostics gained valuable clinical insights into pharma drivers and interests in biomarker applications in general, companion diagnostics, predictive biomarkers and personalised medicine.
The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in SMEs to align project with the top sectors. MLA Diagnostics received funding for a feasibility project to continue assay development and validation.